Rapport Therapeutics, Inc. Common Stock (RAPP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Rapport Therapeutics, Inc. Common Stock in 2026. The next earnings report is expected on November 5, 2026.
Rapport Therapeutics missed consensus estimates in its latest earnings, with EPS of -$1.19 versus an estimate of -$1.1766 and revenue of $0 meeting expectations. In the prior quarter both EPS and revenue came in ahead of expectations, with revenue about 166.7% above estimates.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.